vs
Side-by-side financial comparison of Evolus, Inc. (EOLS) and MEDIFAST INC (MED). Click either name above to swap in a different company.
MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $73.1M, roughly 1.0× Evolus, Inc.). On growth, Evolus, Inc. posted the faster year-over-year revenue change (6.7% vs -36.9%). Over the past eight quarters, Evolus, Inc.'s revenue compounded faster (4.6% CAGR vs -34.4%).
Evolus, Inc. is a medical aesthetics company focused on developing and commercializing non-surgical cosmetic treatment solutions. Its flagship product is a prescription neuromodulator designed to reduce moderate to severe glabellar frown lines, serving licensed aesthetic healthcare providers and consumers across North America, Europe, and key Asia-Pacific regional markets.
Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.
EOLS vs MED — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $73.1M | $75.1M |
| Net Profit | $-10.7M | — |
| Gross Margin | 66.9% | 69.4% |
| Operating Margin | 23.8% | -10.4% |
| Net Margin | -14.6% | — |
| Revenue YoY | 6.7% | -36.9% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.16 | $-1.64 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $73.1M | — | ||
| Q4 25 | $90.3M | $75.1M | ||
| Q3 25 | $69.0M | $89.4M | ||
| Q2 25 | $69.4M | $105.6M | ||
| Q1 25 | $68.5M | $115.7M | ||
| Q4 24 | $78.9M | $119.0M | ||
| Q3 24 | $61.1M | $140.2M | ||
| Q2 24 | $66.9M | $168.6M |
| Q1 26 | $-10.7M | — | ||
| Q4 25 | $130.0K | — | ||
| Q3 25 | $-15.7M | $-2.3M | ||
| Q2 25 | $-17.1M | $2.5M | ||
| Q1 25 | $-18.9M | $-772.0K | ||
| Q4 24 | $-6.8M | — | ||
| Q3 24 | $-19.2M | $1.1M | ||
| Q2 24 | $-11.3M | $-8.2M |
| Q1 26 | 66.9% | — | ||
| Q4 25 | 65.7% | 69.4% | ||
| Q3 25 | 66.5% | 69.5% | ||
| Q2 25 | 65.3% | 72.6% | ||
| Q1 25 | 68.1% | 72.8% | ||
| Q4 24 | 66.7% | 74.1% | ||
| Q3 24 | 68.9% | 75.4% | ||
| Q2 24 | 70.3% | 73.2% |
| Q1 26 | 23.8% | — | ||
| Q4 25 | 4.7% | -10.4% | ||
| Q3 25 | -16.7% | -4.6% | ||
| Q2 25 | -14.7% | -1.0% | ||
| Q1 25 | -22.1% | -1.1% | ||
| Q4 24 | -2.9% | 0.6% | ||
| Q3 24 | -25.3% | 1.5% | ||
| Q2 24 | -11.5% | -4.7% |
| Q1 26 | -14.6% | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | -22.8% | -2.5% | ||
| Q2 25 | -24.7% | 2.3% | ||
| Q1 25 | -27.6% | -0.7% | ||
| Q4 24 | -8.6% | — | ||
| Q3 24 | -31.4% | 0.8% | ||
| Q2 24 | -17.0% | -4.8% |
| Q1 26 | $-0.16 | — | ||
| Q4 25 | $0.01 | $-1.64 | ||
| Q3 25 | $-0.24 | $-0.21 | ||
| Q2 25 | $-0.27 | $0.22 | ||
| Q1 25 | $-0.30 | $-0.07 | ||
| Q4 24 | $-0.11 | $0.08 | ||
| Q3 24 | $-0.30 | $0.10 | ||
| Q2 24 | $-0.18 | $-0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.8M | $167.3M |
| Total DebtLower is stronger | $156.4M | — |
| Stockholders' EquityBook value | — | $198.9M |
| Total Assets | $220.6M | $248.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $49.8M | — | ||
| Q4 25 | $53.8M | $167.3M | ||
| Q3 25 | $43.5M | $173.5M | ||
| Q2 25 | $61.7M | $162.7M | ||
| Q1 25 | $67.9M | $164.6M | ||
| Q4 24 | $87.0M | $162.3M | ||
| Q3 24 | $85.0M | $170.0M | ||
| Q2 24 | $93.7M | $163.5M |
| Q1 26 | $156.4M | — | ||
| Q4 25 | $146.1M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $121.8M | — | ||
| Q4 24 | $121.5M | — | ||
| Q3 24 | $121.2M | — | ||
| Q2 24 | $120.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | $-23.1M | $198.9M | ||
| Q3 25 | $-28.8M | $214.7M | ||
| Q2 25 | $-18.7M | $216.0M | ||
| Q1 25 | $-6.6M | $211.0M | ||
| Q4 24 | $5.5M | $210.1M | ||
| Q3 24 | $5.9M | $207.3M | ||
| Q2 24 | $19.3M | $205.3M |
| Q1 26 | $220.6M | — | ||
| Q4 25 | $225.9M | $248.0M | ||
| Q3 25 | $219.0M | $268.2M | ||
| Q2 25 | $228.8M | $269.3M | ||
| Q1 25 | $213.4M | $280.0M | ||
| Q4 24 | $232.6M | $284.2M | ||
| Q3 24 | $229.6M | $291.2M | ||
| Q2 24 | $233.8M | $293.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 22.00× | — | ||
| Q3 24 | 20.58× | — | ||
| Q2 24 | 6.26× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-5.3M |
| Free Cash FlowOCF − Capex | — | $-6.6M |
| FCF MarginFCF / Revenue | — | -8.8% |
| Capex IntensityCapex / Revenue | — | 1.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $12.8M | $-5.3M | ||
| Q3 25 | $-14.7M | $12.1M | ||
| Q2 25 | $-24.8M | $-3.4M | ||
| Q1 25 | $-15.6M | $3.4M | ||
| Q4 24 | $4.8M | $-4.9M | ||
| Q3 24 | $-5.7M | $9.1M | ||
| Q2 24 | $-6.5M | $13.1M |
| Q1 26 | — | — | ||
| Q4 25 | $11.3M | $-6.6M | ||
| Q3 25 | $-15.6M | $10.8M | ||
| Q2 25 | $-25.5M | $-4.8M | ||
| Q1 25 | $-16.0M | $1.9M | ||
| Q4 24 | $4.4M | $-7.2M | ||
| Q3 24 | $-6.0M | $7.7M | ||
| Q2 24 | $-6.9M | $11.1M |
| Q1 26 | — | — | ||
| Q4 25 | 12.6% | -8.8% | ||
| Q3 25 | -22.7% | 12.0% | ||
| Q2 25 | -36.7% | -4.5% | ||
| Q1 25 | -23.3% | 1.6% | ||
| Q4 24 | 5.5% | -6.1% | ||
| Q3 24 | -9.9% | 5.5% | ||
| Q2 24 | -10.4% | 6.6% |
| Q1 26 | — | — | ||
| Q4 25 | 1.6% | 1.8% | ||
| Q3 25 | 1.4% | 1.5% | ||
| Q2 25 | 1.0% | 1.3% | ||
| Q1 25 | 0.5% | 1.3% | ||
| Q4 24 | 0.6% | 1.9% | ||
| Q3 24 | 0.5% | 1.0% | ||
| Q2 24 | 0.7% | 1.1% |
| Q1 26 | — | — | ||
| Q4 25 | 98.67× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1.36× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 8.04× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EOLS
| Product revenue, net | $72.7M | 99% |
| Service revenue | $390.0K | 1% |
MED
Segment breakdown not available.
